Aurobindo Pharma Board Greenlights Major Rs 800 Crore Share Buyback Initiative
In a significant corporate move, the board of Aurobindo Pharma, a leading generics drug manufacturer based in Hyderabad, has given its approval for a substantial share buyback proposal valued at Rs 800 crore. This strategic decision, announced on Monday, aims to repurchase up to 54.23 lakh fully paid-up equity shares, each with a face value of Rs 1, at a price of Rs 1,475 per share.
Details of the Buyback Proposal and Regulatory Framework
The proposed buyback is contingent upon obtaining necessary regulatory and statutory approvals. It represents approximately 0.93% of the company's total paid-up equity share capital, highlighting a focused effort to enhance shareholder value. Aurobindo Pharma has formally notified the stock exchanges, setting April 17, 2026, as the record date. This date will be crucial for determining shareholder eligibility and entitlement to participate in the buyback.
The buyback will be executed through the tender offer route on a proportionate basis, strictly adhering to the Securities and Exchange Board of India's (SEBI) Buyback Regulations and the provisions of the Companies Act. To oversee this process, the company has already established a dedicated buyback committee, ensuring smooth implementation and compliance.
Eligibility and Potential Adjustments in Buyback Terms
All eligible equity shareholders, including promoters and promoter group entities who hold shares as of the record date, will have the opportunity to take part in this offer. In a notable provision, the board or the buyback committee retains the flexibility to increase the buyback price and correspondingly reduce the number of shares to be repurchased up to one working day before the record date. However, the overall buyback size of Rs 800 crore will remain unchanged, providing stability and predictability for investors.
It is important to note that the Rs 800 crore figure excludes various transaction costs and related expenses, such as brokerage fees, taxes, filing charges, legal costs, and publication expenses. This transparency ensures that shareholders have a clear understanding of the financial implications.
Historical Context and Shareholding Structure
This latest buyback initiative follows a previous offer made less than two years ago, in August 2024, which aggregated to Rs 750 crore at a price of Rs 1,460 per share. The current proposal represents a continuation of the company's strategy to return value to its shareholders through such mechanisms.
As of December 31, 2025, the shareholding pattern of Aurobindo Pharma reveals a diverse investor base. Promoters and promoter group entities hold a majority stake of 51.82%, while mutual funds account for 19.52%, foreign portfolio investors for 13.94%, insurance companies for 5.50%, and public shareholders and others for 7.93%. This distribution underscores the broad interest in the company's performance and the potential impact of the buyback across different investor categories.
The approval of this Rs 800 crore share buyback by Aurobindo Pharma's board marks a pivotal moment in the company's financial planning, aimed at bolstering investor confidence and optimizing capital structure in the competitive pharmaceutical sector.
